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Summary  The  increasing  prevalence  of  multidrug-resistant  and  pan  drug-resistant
Acinetobacter  baumannii  as  a  cause  of  nosocomial  infections  has  led  to  the  need
for  the  reassessment  of  novel  combinations  of  antibiotics  as  our  only  current  viable
option  for  handling  such  infections  until  a  new  therapeutic  option  becomes  available.
Two  of  the  most  commonly  used  methods  for  testing  antimicrobial  synergy  are  the
Time-kill  assay  method  and  the  E-test  method,  and  these  were  the  methods  used
in  this  study.  Antibiotic  combinations  tested  in  this  study  were  azithromycin  and
polymyxin,  tobramycin  and  polymyxin,  polymyxin  and  rifampicin,  and  tobramycin
and  rifampicin.
The  azithromycin  and  polymyxin  combination  showed  synergy,  while  the  rifampicin
and  polymyxin  combination  showed  antagonism.  The  synergy  was  achieved  at  lower
MIC  values  than  using  each  of  the  single  agents  alone  against  the  same  isolates.
Synergy  testing  results  varied  according  to  the  method  used,  and  it  is  difﬁcult  to
establish  which  method  is  more  accurate.  The  use  of  these  lower  MIC  values  as
a  guide  to  determine  effective  therapeutic  doses  used  in  combination  therapy  can
help  to  decrease  the  emergence  of  resistance  and  can  also  minimize  the  side  effects
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associated  with  using  a single  agent  at  a  higher  dose.  Further  research  is  still  required
to  predict  in  vivo  efﬁcacy  of  such  combinations.
©  2015  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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tion) showed  10  distinct  isolates  (Table  1).Limited.  All  rights  reserv
Introduction
Acinetobacter  baumannii  has  emerged  as  a leading
nosocomial  pathogen,  particularly  in  Intensive  Care
Units (ICUs),  where  several  outbreaks  have  been
described [1].  Outbreaks  have  been  increasingly
reported regularly,  and  most  of those  outbreaks
were caused  by  multidrug-resistant  (MDR)  strains
of this  organism  [2]. This  phenomenon  is  due
to the  extraordinary  ability  of  the  organism  to
develop  multiple  resistance  mechanisms  against
the major  antibiotic  classes  used  in  the  ICU,  includ-
ing cephalosporins,  aminoglycosides,  quinolones
and carbapenems  [3].
With the  beginning  of  injudicious  increasing  use
of antibiotics  and  poor  infection  control,  resis-
tance has  emerged  worldwide,  and  there  has  been
an increase  in  recent  reports  of  outbreaks  involv-
ing MDR-AB  that  are  also  carbapenem-resistant
(CR-AB)  [4].  This  phenomenon  has  resulted  in
the resurgence  of  the  polymyxins,  which  are
increasingly used  as  the  last  line  of  defense
against these  difﬁcult-to-treat  infections,  and  as
predicted, rising  reports  of  polymyxin  heteroresis-
tance in  carbapenem-resistant  A.  baumannii  and
even pan  drug-resistant  A.  baumannii  (PDR-AB)
(which is resistant  to  all  used  antibiotics,  including
carpabenem resistance  and  also  polymyxin  resis-
tance)  have  emerged  [5].  This  evidence  shows  that
polymyxins  should  not  be  used  as  monotherapy.
The  antibiotic  development  channel  is  under
pressure from  the  distressing  spread  of  antimicro-
bial resistance,  but  it  is unlikely  that  any  new  drug
will reach  clinical  use  for  at  least  15  years.  In  the
interim,  a  reassessment  of  drugs  that  were  previ-
ously out  of  favor  and  the  investigation  of  novel
combinations of  existing  agents  are  clearly  warran-
ted [6].
In this  situation,  other  than  strict  infection  con-
trol measures,  combination  therapy  may  be  our  only
remaining  practical  therapeutic  option  for  treating
infections  caused  by  such  bacteria.  Therefore,  the
objective  of  this  study  was  to  identify  potential  bac-
tericidal antimicrobial  combinations  against  CR-AB
isolated  in  our  hospital.
A
S
wIn  vitro  combination  susceptibility  testing  poses
 signiﬁcant  challenge  for  clinical  microbiology  lab-
ratories with  lack  of  standardization.  This  study
valuated  the  effects  of  various  antibiotic  combina-
ions against  MDR-AB  and  compared  in  vitro  synergy
esting  results  obtained  from  time-kill  and  E-test
ethods.
aterials and methods
acterial strains
en  isolates  of  A.  baumannii  were  collected  from
en patients  admitted  to  different  intensive  care
nits of  Suez  Canal  University  Hospital  over  the
eriod  of  eight  months  from  June  2011  to  February
012, representing  all  strains  of  the  organism  that
ere isolated  from  patients  conﬁrmed  to  have  dif-
erent types  of  nosocomial  infections  during  that
eriod. These  isolates  were  responsible  for  docu-
ented  bloodstream  infection  (two  isolates),  lower
espiratory  tract  infection  (ﬁve  isolates),  burn
ound  infection  (two  isolates)  and  urinary  tract
nfection  (one  isolate).  Isolates  were  diagnosed  and
dentiﬁed using  the  conventional  methods  in  the
icrobiology  laboratory,  which  included  identiﬁ-
ation  of  colony  morphology  on  solid  media  and
tained  smears,  cytochrome  oxidase  testing,  cata-
ase testing,  indole  testing,  motility  testing,  citrate
tilization  testing,  urease  testing  and  triple  sugar
ron testing.  Isolates  were  then  reconﬁrmed  by
sing the  API  20  NE  system  (biomerieux,  Marcy
’Etoile, France).  Phenotypic  typing  of  strains  using
he antibiogram  and  biotypes  (which  refers  to
ifferent  distinct  panels  of  biochemical  reaction
esults as  tested  using  API  20  NE  and  is  represented
y a different  seven-digit  number  of  API  identiﬁca-ntimicrobial susceptibility testing
usceptibility  patterns  of  A.  baumannii  isolates
ere tested  using  a panel  of  16  antibiotics  including
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Table  1  Biotypes  and  antibiogram  of  studied  A.  baumannii  isolates.
Isolate  1  2  3  4  5  6  7  8  9  10 Frequency/percent
of resistance  To
respective
antibiotic
Site  of  isolation  Respiratory  Respiratory  Respiratory  Respiratory  Respiratory  Blood  Burn  Burn  Blood  Urine
Biotype  0001073
(I)
4041473
(III)
0041073
(II)
4041473
(III)
0041073
(II)
0001073
(I)
5041073
(VI)
0001073
(I)
4001073
(V)
0001473
(IV)
Antibiogram  A  B  B  C  C  D  D  E  E  A
Piperacillin R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Piperacillin-
tazobactam
R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Ampicillin-
sulbactam
R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Ceftazidime  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Cefepime  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Cefotaxime  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Ceftriaxone  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Imipenem  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Meropenem  R  R  R  R  R  R  R  R  8/10  (80%)
Gentamycin  R  R  R  R  R  R  6/10  (60%)
Tobramycin  R  R  R  R  R  R  R  R  8/10  (80%)
Amikacin  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Tetracycline  R  R R  R  4/10  (40%)
Ciproﬂoxacin  R  R  R  R  R  R  R  R  R  R  10/10  (100%)
Levoﬂoxacin  R  R  R  R  R  R  R  R  8/10  (80%)
Trimethoprim-
sulphmethoxazole
R  R  R  R  R  R  R  R  R  R  10/10(100%)
Note: Isolates used for synergy studies were [1-3-4-5-6-7-8-9]. Circled letters show that results of these strains (sensitive or intermediate resistance) are different from the rest of
strains which are all resistant.
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piperacillin,  piperacillin-tazobactam,  ampicillin-
sulbactam,  ceftazidime,  cefepime,  cefotaxime,
ceftriaxone, imipenem,  meropenem,  gentamycin,
tobramycin, amikacin,  tetracycline,  ciproﬂoxacin,
levoﬂoxacin, and  trimethoprim-sulphmethoxazole,
as shown  in  Table  1, and  this  was  done  using  a
modiﬁed Kirby  Bauer  method  following  the  CLSI
guidelines  of  2011  [7].
Antimicrobial agents and MIC determination
Minimum  Inhibitory  Concentrations  (MICs)  of
tobramycin,  polymyxin,  rifampicin  and  azithrom-
ycin were  tested  using  the  agar  dilution  method
according to  the  Clinical  and  Laboratory  Standards
Institute protocol  [8,9]. Breakpoints  were  inter-
preted  according  to  CLSI  2014  [10]. Escherichia  coli
ATCC 25922  was  used  as  a  quality  control  strain.
Laboratory-grade  standard  reference  powders
of the  following  antimicrobials  were  obtained  and
reconstituted  according  to  the  manufacturer’s
instructions:  tobramycin,  rifampicin,  polymyxin
B sulfate  (Sigma  chemical  company),  and
azithromycin (Pﬁzer).  Solutions  of  antibiotics  with
different concentrations  were  freshly  prepared  on
the day  of  the  experiment.
Results  of  the  susceptibilities  of  the  four  men-
tioned antibiotics  against  study  isolates  are  shown
in Table  2.
Synergy studies
Distinct  isolates  were  chosen  randomly  from  differ-
ent antibiogram  types  and  different  biotypes,  and
three different  random  distinct  non-duplicate  iso-
lates were  tested  for  in  vitro  synergy  for  each  of
the chosen  four  combinations  using  both  the  E-test
assay  and  the  time-kill  method  [11,12].
The antibiotic  combinations  tested  were
tobramycin +  polymyxin,  azithromycin  +  polymyxin,
tobramycin +  rifampicin,  and  polymyxin  +
rifampicin. These  combinations  were  selected
based on  previously  published  data  that  demon-
strated a  high  likelihood  of  achieving  in  vitro
synergy and  also  considering  the  availability  of
these antibiotics  [13,14].
E-test assay
Bacterial  inoculums  matched  to  the  McFarland
standard of  0.5  were  inoculated  on  Muller  Hinton
agar (Oxoid,  Basingstoke,  UK).  E-test  strips  (Hime-
dia, India)  were  placed  on  Muller  Hinton  agar  in  a
◦cross formation  with  a  90 angle  at  the  intersec-
tion between  the  scales  at  their  respective  MIC  for
the organism.  After  incubation  for  18  h  at  35 ◦C,  the
zone of  inhibition  was  read  as  the  value  where  the
(
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clipse  zone  of  inhibition  intersected  the  scale  on
he E-test  strip[15].
The fractional  inhibitory  concentration  (FIC)
ndex was  calculated  as  the  FIC  of  drug  A  + FIC  of
rug B
FIC  of  drug  A  =  MIC  of  drug  A  in  combination/MIC
f drug  A  alone
FIC of  drug  B  = MIC  of  drug  B  in  combination/MIC
f drug  B  alone
Result readings
 Synergy  was  determined  by  FIC  index  ≤0.5
 Indifference  was  determined  by  FIC  index  >0.5
but ≤4
 Antagonism  was  deﬁned  by  FIC  index  >4
ime-kill  assay  studies
ubes  containing  freshly  prepared  Muller  Hinton
roth were  supplemented  with  the  drugs  at  concen-
rations  corresponding  to  two  times  the  MIC  (when
ntagonism  was  expected  by  the  E-test  method),
hile tubes  were  supplemented  with  1/4—1/8  the
IC for  each  tested  drug  (when  synergism  was
xpected). Tubes  were  then  inoculated  with  A.
aumannii  isolates  at  a density  of  6  *  105 CFU/ml
n a  ﬁnal  volume  of  10  ml  after  organisms  were
rown on  Muller  Hinton  broth  for  4 h  (log  phase
f growth).  Tubes  were  vortexed  gently  and  incu-
ated at  35  ±  2 ◦C.  A  growth  control  was  included.
liquots (0.1  ml  of  broth)  were  removed  from  tubes
t times  0,  3,  6,  and  24  h post-inoculation  and  seri-
lly diluted  in  saline  for  determination  of  viable
ounts. Diluted  samples  (100  l)  were  plated  in
uplicate  on  trypticase  soy  agar  plates,  and  total
acterial  counts  were  determined  after  18  h  of
ncubation  at  37 ◦C.
The  bactericidal  activity  was  deﬁned  as  = 3
og10 CFU/ml  reduction  in  the  colony  count  relative
o the  initial  inoculums  [16].
The deﬁnition  of  synergism  was  met  when  there
as a  ≥2  log10 CFU/ml  decrease  by  the  combination
ompared with  the  most  active  single  agent.
The drug  combination  was  considered  antago-
istic when  there  was  a  ≥2  log10 CFU/ml  increase
y the  combination  compared  with  the  most  active
ingle agent  [17].
The  shortest  period  necessary  to  obtain  syner-
ism was  determined  [11,12].
tatistical and mathematical analysis
ata  entry  was  done  using  Microsoft  Excel  2007.
Data analysis  was  done  using  SPSS  version  16.0
SPSS Inc,  Chicago,  IL,  USA).
Two-factor  analysis  of  variance  (ANOVA)  was
sed in  factorial  experiments  to  test  for  differences
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Table  2  Acinetobacter  baumannii  isolates  respective  MICs  as  determined  by  agar  dilution  method  against  the  four
antibiotics  used  to  test  synergy.
isolate  Rifampicin  MICa Polymyxin  MIC  Azithromycin  MIC  Tobramycin  MIC
1  0.06  0.5  [S]  4  8  [I]
2  0.06  0.5  [S]  4  16  [R]
3  0.5  0.25  [S]  0.5  8  [I]
4  1  0.125  [S]  256  256  [R]
5  4  0.25  [S] >256  256  [R]
6  0.5 0.25  [S] 64  16  [R]
7  <0.008 0.125  [S] 0.125 32 [R]
8  0.06  0.125  [S]  0.125  256  [R]
9  0.06  0.125  [S]  0.125  16  [R]
10  <0.008  0.125  [S]  0.5  1  [S]
S, sensitive, I, intermediate, R, resistant.
Break points were determined according to CLSI 2014 [10].
No breakpoints are recommended for rifampicin or azithromycin versus Acinetobacter either by EUCAST or by CLSI.
b
c
c
t
R
A
A
i
d
i
t
c
a
s
g
ﬂ
r
d
u
d
t
t
p
R
m
A
t
a
b
a
r
w
f
s
t
w
i
w
t
t
R
T
a
F
t
s
T
M
s
i
a
a
v
e
l
l
ea MIC, minimum inhibitory concentration.
etween  combinations  of  drugs  used  and  single  drug
oncentrations  over  time.
A Tukey  test  for  post  hoc  analysis  was  used  to
ompare AUC0—24 values  between  groups.
A statistical  P  value  of  ≤0.05  was  considered  sta-
istically  signiﬁcant.
esults
ntimicrobial susceptibilities
cinetobacter  baumannii  were  discriminated
nto ﬁve  patterns  or  antibiograms  by  using  disk
iffusion  methods  for  susceptibility  testing.  All
solates were  resistant  to  piperacillin,  piperacillin-
azobactam, ampicillin-sulbactam,  ceftazidime,
efepime, cefotaxime,  ceftriaxone,  imipenem,
mikacin, ciproﬂoxacin,  and  trimethoprim-
ulphamethoxazole.  Susceptibility  to  meropenem,
entamycin, tobramycin,  tetracycline,  and  levo-
oxacin  enabled  the  deﬁnition  of  ﬁve  phenotypic
esistance patterns  (A-E)  that  were  equally
istributed (20%  each).
Results  of  susceptibilities  of  the  four  antibiotics
sed in  synergy  studies  against  study  isolates  when
etermined  by  the  agar  dilution  method  showed
hat all  isolates  were  susceptible  to  polymyxin  and
hat 70%  were  tobramycin  resistant.  The  complete
roﬁle is  shown  in  Table  2.
esults of  the E-test combination testing
ethod
ntibiotic  combinations  were  tested  using  the  E-
est method  after  the  MIC  was  determined  using  the
(
i
r
(gar  dilution  method.  Table  3  shows  MICs  obtained
y the  agar  dilution  method  for  single  antibiotics
nd MICs  obtained  with  the  E-test  method  for  the
espective  antibiotic  combinations.  The  FIC  index
as calculated  and  interpreted  according  to  the
ormula  described  in  the  materials  and  methods
ection. The  azithromycin  and  polymyxin  combina-
ion showed  synergistic  results  in  the  tested  strains,
hile rifampicin  and  polymyxin  showed  antagonism
n all  tested  strains.  Indifference  was  detected
hen testing  tobramycin  and  polymyxin  in  one
ested  strain  and  tobramycin  and  rifampicin  in  two
ested strains.
esults of the time-kill assay
he  same  previously  mentioned  combinations  were
lso tested  using  the  time-kill  assay  method.
irst, when  tobramycin  and  rifampicin  combina-
ions were  tested,  there  were  three  different
cenarios with  the  three  different  tested  isolates:
he ﬁrst  was  testing  1/4  MIC  of  tobramycin  +  1/4
IC of rifampicin  on  isolate  number  6,  and  this
howed bactericidal  activity  (3-fold  log  reduction
n cell  numbers  compared  to  starting  inoculums)
t 6  h.  No  bacterial  regrowth  occurred  at  24  h,
nd there  was  about  a 4  log  difference  in  the
iable count  compared  with  cells  treated  with
ither rifampicin  or  tobramycin  alone  and  a >3-fold
og reduction  compared  with  the  starting  inocu-
ums.  The  difference  between  the  combination  and
ach tested  drug  alone  was  statistically  signiﬁcant
P =  0.000).  Signiﬁcant  differences  were  detected
n synergistic  activity  between  combinations  when
egimens  were  compared  at  the  24-h  readings
P =  0.04  and  P =  0.000,  respectively)  (Fig.  1).
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Table  3  results  of  E-test  combination  against  different  antibiotics.
Antibiotic  combinations  Isolates
tested
MIC  AZM  MIC  AZM  +  PB  MIC  PB  MIC  PB  +  AZM  FIC  index  Interpretation
Azithromycin
and  Polymyxin
1 4  0.01  0.5  0.01  0.0225  Synergistic
6  64  0.1  0.25  0.1  0.401  Synergistic
8  0.125 0.01  0.125  0.01  0.16  Synergistic
Antibiotic  combinations Isolates
tested
MIC NN  MIC  NN  +  PB  MIC  PB  MIC  PB  + NN  FIC  index  Interpretation
Tobramycin  and
Polymyxin
4  265  10  0.125  0.03  0.23  Synergistic
7  32  30  0.125  1  8.9  Antagonistic
9  16  4  0.125  0.1  1.05  Indifferent
Antibiotic  combinations  Isolates
tested
MIC  NN  MIC  NN  +  RIF  MIC  RIF  MIC  RIF  +  NN  FIC  index  Interpretation
Tobramycin  and
Rifampicin
1  8  1  0.06  2  33.125  Antagonistic
3  8  1.5  0.5  1  2.187  Indifferent
6  16  1.5  0.5  1  2.093  Indifferent
Antibiotic  combinations  Isolates
tested
MIC RIF  MIC  RIF  +  PB  MIC  PB  MIC  PB  +  RIF  FIC  index  Interpretation
Rifampicin
and  polymyxin
4 1 32  0.125  0.01  32.04  Antagonistic
5  4 32  0.25  0.01  8.04  Antagonistic
8  0.06 1  0.125  0.1  17.46  Antagonistic
NN, tobramycin, RIF, rifampicin, AZM, Azithromycin, PB, polymyxin.
rifampicin  alone.  The  difference  between  the
combination and  each  tested  drug  alone  was  statis-
tically signiﬁcant  (P  = 0.000  and  0.01,  respectively)
(Fig.  2).
The  third  testing  was  tobramycin  and  rifampicin
on isolate  1;  although  tobramycin  and  the  combi-
nation showed  bactericidal  activity  at  6 h, a  rapid
regrowth  of  cells  occurred  at  24  h,  showing  a  5  log
difference  between  the  combination  and  the  use
of tobramycin  alone  and  only  1  log  difference  com-
pared to  the  starting  inoculum.  The  difference  was
statistically  signiﬁcant  (P  =  0.000)  (Fig.  3).
When  the  azithromycin  and  polymyxin  combina-
tion was  tested  for  isolate  6,  bactericidal  activityFigure  1  Time  kill  results  for  tobramycin  +  rifampicin
against  Acinetobacter  baumannii  isolate  6.
The  second  testing  was  2MIC  tobramycin  + 2MIC
rifampicin. This  combination  showed  no  bacteri-
cidal activity  at  6  h,  and  the  viable  cell  count
was the  same  at  24  h  compared  to  that  of  using
Figure  2  Time  kill  results  for  tobramycin  +  rifampicin
against  Acinetobacter  baumannii  isolate  3.
was achieved  at  6  h  by  azithromycin  alone  with
Figure  3  Time  kill  results  for  tobramycin  +  rifampicin
against  Acinetobacter  baumannii  isolate  1.
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aigure  4  Time  kill  results  for  azithromycin  +  polymyxin
gainst  Acinetobacter  baumannii  isolate  6  (A).
egrowth  by  2  logs  at  24  h.  Although  there  was  no
bserved  log  decrease  in  the  1/4  azithromycin  +  1/4
olymyxin  combination  at  6 h,  there  was  a  rapid
ecrease  by  6 logs  to  reach  zero  bacterial  cells  at
4 h with  the  combination.  The  difference  between
he combination  and  1/4  polymyxin  was  statisti-
ally signiﬁcant  (P  =  0.000),  while  that  between  the
ombination  and  1/4  azithromycin  was  statistically
nsigniﬁcant (P  =  0.14)  (Fig.  4).
When  using  the  combination  of  1/4
zithromycin  +  1/8  polymyxin,  there  was  bac-
ericidal  activity  at  6  h  that  decreased  to  zero
acterial cells  at  24  h (Fig.  5).  The  difference
etween the  combination  and  each  tested  con-
entration  alone  was  statistically  signiﬁcant
P = 0.000).
Isolate  8  showed  a  synergistic  effect  at  a  concen-
ration of  1/4  azithromycin  + 1/4  polymyxin,  while
solate  1  showed  indifference  for  all  tested  concen-
rations.
omparison of the results obtained by the
-test and time-kill methods
he  degree  of  agreement  between  the  methods
f testing  synergy  ranged  from  33%  in  one  tested
ombination to  66%  in  three  tested  combinations.
able  4  shows  detailed  results  comparing  the  degree
f agreement  between  the  TKA  and  E-test  regarding
ifferent  antibiotic  combinations.
igure  5  Time  kill  results  for  azithromycin  +  polymyxin
gainst  Acinetobacter  baumannii  isolate  6  (B).
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anagement  of  MDR-AB  infection  is  a medical  con-
ern because  of  the  limited  therapeutic  options
vailable and  the  tendency  of  infection  to  occur  in
ritically  ill  hosts  with  limited  physiologic  reserve.
n this  scenario,  combination  therapy  has  [18]
ecome  the  ultimate  resource  to  treat  MDR  and
an-resistant  A.  baumannii  infections.
Various in  vitro  studies  showed  different  results
sing different  methods.  Our  results  showed  that
he type  of  interaction  was  to  some  extent  method-
ependent.
Synergy testing  methods  are  not  standardized  for
eproducibility  and  interpretation,  and  therefore,
t is  extremely  difﬁcult  to  compare  these  methods’
esults from  different  studies  [19]. Two  methods  to
etect in  vitro  synergy  were  used  in  our  study:  the
-test method  and  the  time-kill  assay  method.  The
-test method  is  easy  to  perform  on  solid  media
nd is more  suitable  for  in  vitro  experiments  aim-
ng to  mimic  in  vivo  conditions.  It  is  considered
 relatively  new  method  for  determining  synergy;
owever, it  is not  standardized  as  there  are  3  dif-
erent recently  described  methods  (a prediffusion
echnique, E-test  strips  placed  side  by  side,  or  E-
est strips  placed  in  a cross  formation),  but  it  has
he potential  to  be  a useful  screening  test  for  the
etermination  of  synergy  [19,20].
Although  time-consuming  and  cumbersome,  the
ime-kill assay  (TKA)  provides  a dynamic  picture  of
ntibiotic action  over  time;  however,  it  is  too  labor
ntensive  for  use  in  routine  diagnostic  laboratories
nd is  unlikely  to  provide  results  in  a  clinically  rel-
vant time  frame  [20].  In the  time-kill  assay  for
ynergy,  drug  concentrations  are  ﬁxed  and  do  not
ecrease  over  time  as  they  would  in  vivo.  Addition-
lly, there  are  no  standard  concentrations  at  which
ntibiotics  are  tested.  The  inoculum  size  and  time
rame of  the  time-kill  assay  add  more  variability
o the  test.  The  time  parameter  of  24  h  can  limit
r alter  the  results  of  the  experiment  if  regrowth
ccurs with  one  or  both  antibiotics.  Regrowth  can
e caused  by  use  of  sub-inhibitory  concentrations  of
ntibiotics. Emergence  of  resistant  subpopulations
ay also  account  for  the  regrowth,  or  regrowth
ay be  due  to  bacteria  that  adhere  to  the  surface
f the  bottle  and  are  subsequently  released  into
he medium.  Another  factor  affecting  regrowth  is
nactivation  of  the  antibiotics  in  vitro  [19].
Looking at  the  azithromycin  and  polymyxin  com-
ination,  synergy  was  found  in  3/3  (100%)  isolates
sing  the  E-test  method  and  2/3  (66.6%)  isolates
sing the  TKA.  One  isolate  was  synergistic  by
he E-test  method  (FIC  =  0.0225)  but  indifferent
y the  TKA  method  (log10 change  =  1.5).  This  is
600  W.  Nageeb  et  al.
Table  4  Degree  of  agreement  between  TKA  and  E-test  against  different  used  antibiotic  combination.
Isolate  MIC  results  E-test  interpretation  Time  kill  interpretation
AZMa PB
1  4  0.5  [s]  Synergy  Indifference
6  64  0.25  [s] Synergy  Synergy
8  0.125  0.125  [s]  Synergy  Synergy
Isolate  MIC  results  E-test  interpretation  Time  kill  interpretation
NN  PB
4  256  [R] 0.125  [s] Synergy  Indifference
7  32  [R] 0.125  [s] Antagonism  Indifference
9  16  [R] 0.125  [s] Indifference  Indifference
Isolate  MIC  results  E-test  interpretation  Time  kill  interpretation
NN  RIFa
1  8  [I]  0.06  Antagonism  Antagonism
3  8  [I]  0.5  Indifference  Indifference
6  16  [R]  0.5  Indifference  Synergy
Isolate  MIC  results  E-test  interpretation  Time  kill  interpretation
PB  RIFa
4  0.125  [S]  1  Antagonism  Antagonism
5  0.25  [S]  4  Antagonism  Indifference
8  0.125  [S]  0.06  Antagonism  Antagonism
NN, tobramycin, RIF, rifampicin, AZM, azithromycin, PB, polymyxin, I, intermediate, R, resistant, S, sensitive.
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consistent  with  the  results  of  Appleman  et  al.
[21]  who  reported  synergy  between  the  tested
combination. These  results,  however,  are  not  con-
sistent with  those  of  other  researchers  who  failed
to show  synergy  when  combining  azithromycin  and
polymyxin  using  the  E-test-agar  dilution  and  com-
bined E-test  strip  method.  This  may  be  due  to  the
use of  different  methodology  in  this  research  for
testing  synergy,  which  incorporated  one  antibiotic
(polymyxin in  this  study)  into  Isosensitest  agar  at
0.25 X  the  agar  MIC  for  each  strain  tested  and
then inoculated  plates  with  0.5  McFarland  suspen-
sions  of  each  isolate,  followed  by  the  application
of azithromycin  E-test  strips  to  test  synergy.  Follow-
ing incubation  for  24  h  at  37 ◦C,  the  strips  were  read
and the  E-test  MICs  compared  to  a  series  performed
in the  absence  of  polymyxin,  and  this  difference
in results  can  conclude  that  this  method  has  lower
sensitivity  in  detecting  weak  degrees  of  synergy
[22].
Regarding  the  polymyxin  and  rifampicin  com-
bination, antagonism  was  observed  in  3/3  (100%)
isolates  when  using  the  E-test  and  in  2/3  (66.6%)
isolates when  using  the  TKA.  One  isolate  was
antagonistic by  the  E-test  method  (FIC  =  8.04)  but
w
t
indifferent  by  the  TKA  method  (log10 change  =  1).
hese results  do  not  agree  with  those  reported
n the  literature,  as  the  best  studied  combina-
ion involved  rifampicin  with  polymyxin,  which  has
hown synergistic  in  vitro  activity  against  MDR-AB
trains in  most  studies  [13], although  not  consis-
ently,  as  reported  by  Tripodi  et  al.  [14].
The tobramycin  and  polymyxin  combination
howed  highly  variable  results.  By  TKA,  indifference
as observed  in  all  three  tested  strains,  whereas
y using  the  E-test  method,  one  strain  showed
ynergy (FIC  =  0.23),  another  one  showed  indif-
erence  (FIC  =  1.05),  and  the  third  one  showed
ntagonism (FIC  =  8.9).
Regarding rifampicin  and  tobramycin,  two
trains showed  agreement  between  the  E-test
ethod and  TKA,  one  showed  antagonism  against
he same  strain  tested  by  the  two  methods,  another
howed  indifference  when  tested  by  both  methods,
hile  the  third  strain  showed  indifference  when
sing  the  E-test  method  (FIC  =  2.093)  and  synergy
hen using  TKA  (log10 change  =  3.5).
Because  there  is  no  gold  standard  for  synergy
esting, it  is difﬁcult  to  establish  which  method
s more  accurate.  Our  results  demonstrated  that
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Rynergy  studies  of  resistant  Acinetobacter  baumann
he  type  of  interaction  is  to  some  extent  method-
ependent, and  it  is  very  difﬁcult  to  compare  our
esults with  those  of  different  studies.  The  reason
or the  discrepancies  may  be  explained  by  either
ifferent E-test  testing  procedures  used  to  assess
ynergy  or  a  difference  in  strain  selection  for  the
tudy.
The agreement  between  our  E-test  method  and
KA ranged  from  33.3%  to  66.6%,  and  this  to  some
xtent agrees  with  the  study  by  Bonapace  et  al.
23],  which  included  10  strains  of  Acinetobacter
aumannii  (the  same  number  used  in  this  study)
nd showed  that  agreement  between  the  E-test  and
ime-kill  assay  ranged  from  42%  to  97%.  However,
ur results  differ  from  those  of  White  et  al.  [15],
ho showed  agreement  between  the  two  methods
anging from  63%  to  75%  and  found  that  correlation
epended on  the  bacterium  tested  and  the  antibi-
tic combination  tested  [15].
To make  a  useful  clinical  application  of  these
esults, we  can  use  the  MIC  values  measured
ogether with  the  half-life  or  the  dose  interval
o calculate  the  highest  concentrations  reached
n plasma  by  the  studied  drug.  The  previous  data
ogether  with  other  calculated  pharmacological
ata, such  as  volume  distribution  and  systemic
vailability, will  help  calculate  the  best  dose  that
an be  used  to  decrease  the  unnecessary  use  of
igher  doses  that  can  favor  the  emergence  of  resis-
ance.
As mentioned  previously,  in  vitro  testing  has  sev-
ral limitations  related  to  the  relatively  constant
ature of  study  parameters  under  test  tube  condi-
ions and  also  the  absence  of  interactions  between
he antibiotic  at  the  tested  concentration,  the  bac-
erial population  and  the  physiology  of  the  living
ystem.
Despite  these  limitations,  in  vitro  testing  using
hese  methodologies  that  aims  to  mimic  in  vivo  con-
itions is  still  required  before  in  vivo  animal  studies
r further  controlled  clinical  trials.
onclusion
he  azithromycin  and  polymyxin  combination  is
ecommended  for  the  treatment  of  Acinetobac-
er infection.  This  can  be  translated  into  a  useful
herapeutic  strategy  by  combining  the  results  of
ower proven  effective  MIC  values  with  additional
harmacokinetic  and  pharmacodynamic  data  to  cal-
ulate the  effective  therapeutic  dose  of  such  a
ynergistic  combination  in  clinical  practice.  This
ill help  in  decreasing  the  emergence  of  resis-
ance as  a  result  of  the  previously  used  improper601
oses,  which  are  empirical  and  are  not  based  on
aboratory-measured  MIC,  and  it  can  also  decrease
he side  effects  associated  with  the  use  of  single
gents at  higher  doses.  Testing  different  syner-
istic combinations  in  animal  models  should  be
erformed,  and  controlled  clinical  studies  are  fur-
her needed.
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